Anixa Biosciences Reports Q2 2025 Results: No Revenue, Reduced Losses Amid Ongoing Trials

ANIXA BIOSCIENCES, INC. (NASDAQ: ANIX) has released its quarterly report for the period ending April 30, 2025, revealing a mix of financial and operational developments.

Key Financial Highlights:

• Revenue: Zero revenue reported for both Q2 2025 and Q2 2024.
• Net Loss:
  • Q2 2025: $(2.81) million vs. $(3.18) million in Q2 2024.
  • Total for the six months: $(6.03) million vs. $(6.47) million in 2024.
• Cash and Short-term Investments: $15.6 million as of April 30, 2025, down from $19.9 million at the end of October 2024.
• Operating Expenses:
  • Total operating expenses for Q2 2025: $3.00 million compared to $3.47 million in Q2 2024.
  • Research and Development (R&D) Expenses: $1.32 million in Q2 2025, compared to $1.65 million in Q2 2024.
  • General and Administrative Expenses: $1.68 million, down from $1.82 million in Q2 2024.

Positive Aspects:

• Decrease in net loss indicates enhanced efficiency and expense management.
• R&D expenses saw minor reductions, reflecting strategic cost management.
• Cash reserves remain adequate for operations, indicating good liquidity.

Negative Aspects:

• Continued lack of revenue from therapeutic and vaccine programs raises concerns about long-term growth.
• Heavy reliance on funding through stock offerings without immediate return on investments could be risky.
• High cumulative losses totaling $(246.72) million indicate ongoing financial challenges.

Operational Developments:

• The company’s subsidiary, Certainty Therapeutics, is engaged in clinical trials for CAR-T cell therapy focused on ovarian cancer.
• Positive anecdotal results reported from recent trials, with some patients showing signs of efficacy.
• Plans to initiate a Phase 2 vaccine trial for breast cancer upon completion of Phase 1 data review.

Anixa is navigating through a challenging financial landscape while pursuing innovative cancer therapeutics. Ongoing trials and strategic cost management are critical as the company seeks to transition from development to revenue generation.